Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

RIMA

From PsychonautWiki Archive
Revision as of 07:12, 25 October 2018 by >David Hedlund (<ref>{{ cite book | author = Massaro, E. J. | title = Handbook of Neurotoxicology | publisher = Humana Press | location = Totowa, NJ | year = 2002 | isbn = 0-89603-796-7 | url = https://books.google.com/books?id=2c2K-epbCDQC&pg=PA237&lpg=PA237&dq=harmalin)
Jump to navigation Jump to search

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Reversible inhibitors of monoamine oxidase A (RIMAs) are a class of drugs which selectively and reversibly inhibit the enzyme monoamine oxidase A (MAO-A). They are used clinically in the treatment of depression and dysthymia, though they have not gained widespread market share due to limited efficacy relative to other antidepressants. Because of their reversibility and selectivity, RIMAs are safer than the older monoamine oxidase inhibitors (MAOIs).[1]

While safer than general MAOIs, RIMAs still have highly dangerous and sometimes fatal interactions with many common drugs; in particular, they can cause serotonin syndrome or hypertensive crisis when combined with almost any antidepressant or stimulant, common migraine medications, certain herbs, or even most cold medicines (including decongestants, antihistamines, and cough syrup).

Examples

Pharmaceuticals

  • Moclobemide (commonly known by the trade names Amira, Aurorix, Clobemix , Depnil and Manerix)

References

  1. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833271/
  2. Massaro, E. J. (2002). Handbook of Neurotoxicology. Totowa, NJ: Humana Press. p. 237. ISBN 0-89603-796-7. 

See also